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Whales have 1000-fold more cells than humans and mice have 1000-fold
fewer; however, cancer risk across species does not increase with the
number of somatic cells and the lifespan of the organism. This observation
is known as Peto’s paradox. How much would evolution have to change
the parameters of somatic evolution in order to equalize the cancer risk
between species that differ by orders of magnitude in size? Analysis of
previously published models of colorectal cancer suggests that a two- to
three-fold decrease in the mutation rate or stem cell division rate is enough
to reduce a whale’s cancer risk to that of a human. Similarly, the addition
of one to two required tumour-suppressor gene mutations would also be
sufficient. We surveyed mammalian genomes and did not find a positive
correlation of tumour-suppressor genes with increasing body mass and
longevity. However, we found evidence of the amplification of TP53 in
elephants, MAL in horses and FBXO31 in microbats, which might explain
Peto’s paradox in those species. Exploring parameters that evolution may
have fine-tuned in large, long-lived organisms will help guide future experi-
ments to reveal the underlying biology responsible for Peto’s paradox and
guide cancer prevention in humans.1. Background
It is an open question why an elephant, with 100 more cells than a human, or
a whale with 1000 more cells than a human, has approximately the same (or
lower) cancer risk as a human [1]. This is Peto’s paradox, and though many
potential solutions have been proposed, it remains unsolved [2–5]. The fact
that cancer rates are approximately constant across body sizes and lifespans
suggests that there has been selection on the life histories of organisms to pre-
vent cancer in large, long-lived organisms [2,3]. In order to investigate Peto’s
paradox, it would be helpful to understand how much evolution would have
to change the parameters of somatic evolution to compensate for the evolution
of large bodies and long lifespans. For example, we can ask how much the
somatic mutation rate must decrease in order for a whale, which has 1000
more cells than a human, to retain the same cancer risk as a human.
Computational models of cancer risk [3,6–10] can be used in comparative
oncology to estimate how cancer risk should scale across body size and life-
span, and to test how much mutation rate, generation time, number of stem
cells and the number of mutations would have to evolve to compensate for
the evolution of large bodies and long lifespans. We used an algebraic model
[7,11] and a Wright–Fisher model [6], which are generally similar, except
that the Wright–Fisher model allows for cell lineage death (figure 1a,b). We
then used the available genomic data for mammals to look for evidence that
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Figure 1. Estimated risk of colorectal cancer relative to body size under an algebraic and Wright – Fisher model. In the algebraic model (a) [7], cell lineages
accumulate mutations over time, which are passed on to their daughter cell in the next generation and there is no cell death. In the Wright – Fisher model
(b) [6], cells gain mutations over time, but each lineage has a chance of dying and being eliminated from the population. In both models, cancer occurs
when a cell accumulates k mutations. The single light blue cell represents the zygote to show that all cells came from a single initial lineage. The probability
was calculated using the algebraic and Wright – Fisher models with the parameters listed in table 1 [7] (c). Blue/green dots for mouse, human and whale indicate
the estimated risk of colon cancer occurring within 90 years of life given the approximate number of cells in a human colon, 1000 times fewer cells to represent the
mouse, and 1000 times more cells to represent the whale. The red dot indicates the lifetime risk of colon cancer according to the American Cancer Society which is
about 5.3% for men and women averaged together [12]. The estimated age incidences of cancer for whale and human, given the algebraic model, are shown in (d )
and (e), respectively. (c – e) Adapted from [2] with permission from Elsevier.
Table 1. Model parameters. These parameters were used for the algebraic





the number of tumour-suppressor genes may have increased
to compensate for large bodies and long lifespans.Parameter values were taken from [7]. The mutation rate assumes that
there are three genes (1 kb each) per pathway and a background mutation
rate of 1029 mutations per base pair per cell division.
parameter value definition
u 3  1026 mutations/oncogenic
pathway/cell division
d age(days)/4 divisions since birth
(rate ¼ 1 div./4 days)
k 6 rate liming mutations
required for cancer
N 8 effective stem cells per
crypt
m (1.5  1023 – 1.5  1010) crypts per colon2. Results
(a) Model 1: algebraic model of cancer incidence
Calabrese and Shibata [7] devised a simple mathematical
equation to express the probability of a human developing
colorectal cancer given their age that closely matches the
SEER cancer incidence data [13]. The probability of an indi-
vidual developing colorectal cancer after a given number of
stem cell divisions is
p ¼ 1 (1 (1 (1 u)d)k)Nm,
where u is the mutation rate per gene, per division; d is the
number of stem cell divisions since birth; k is the number of
rate-limiting mutations required for cancer to occur; N is
the number of effective stem cells per crypt and m is the
number of crypts per colon [7].
We varied the parameter m from 1.5  103 to 1.5  1010 to
see how the total number of stem cells in the colon changes
the lifetime (90 year) risk of developing colorectal cancer
(figure 1b). Estimates from human and mouse suggest that
for every order of magnitude increase in body size, thenumber of crypts increases proportionally (see §4 Material
and methods). Each crypt likely houses a similar number of
stem cells so this corresponds to a proportional increase in
stem cell number. Otherwise, we used the same parameter
values as Calabrese and Shibata (table 1) to allow an easy
3.0 × 10–9
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Figure 2. Estimated somatic mutation rates scaling with size. Mutation rate estimates show that a 3.2-fold decrease enables an animal that is 1000 larger (and so
with 1000 more stem cells) than a human to have the same cancer risk. The mutation rates shown in the plot resulted in cancer risk predictions for the given





comparison with their original results, though these are esti-
mates and some measurements (e.g. stem cell division rates)
are still under investigation.
If a blue whale has m ¼ 1.5  1010 colonic crypts, this
model predicts that all blue whales would have colorectal
cancer by age 90 (figure 1c). More specifically, when we
solve the equation for years 0–90, we find over 50% of blue
whales would have colorectal cancer by age 50 and all
would have colorectal cancer by age 80 (figure 1d ). The esti-
mate for an animal 1000 times smaller than a human (e.g. a
mouse) is barely above zero even after 90 years. In reality, a
mouse only lives a maximum of 4 years [14], so based on
this equation they should never get colorectal cancer (figure
1c). The chance of an individual person getting colorectal
cancer by age 90 is about 2.5% according to this model
(figure 1c,e) and 5.3% as reported by the American Cancer
Society [12]. It is implausible that 100% of blue whales actu-
ally get colorectal cancer by age 80. Though we do not know
how often blue whales get colorectal cancer, they have been
reported occasionally to have other cancers [15,16] and can
live for over 100 years [14].
Next, we investigated the set of parameter values that would
allow the estimated age incidence of colorectal cancer in large
animals to be similar to that of humans. We tested 10 000
mutation rates ranging from 3  1028 to 3  1025. A mere 3.2-
fold decrease in mutation rate can account for a 1000-fold
increase in body size (figure 2). The somatic mutation rates for
an elephant and whale would need to be 4.6  10210 and
3.13 10210, respectively, in order for them to each have the
same age incidence of colon cancer as humans (figure 2).
Additionally, we tested if altering the number of hits
required for carcinogenesis (k) could allow cancer rates to be
approximately equal across many orders of magnitude in
size. We found that increasing the number of hits required
for cancer was a powerful tumour suppressive mechanism.
Keeping all other parameters consistent with the values listed
in table 1, we varied k to range from 6 to 10. With 10 required
hits, an animal 1000 larger than a human would have lessthan a 0.002% chance of getting cancer by age 90. However,
just two extra hits (i.e. k ¼ 8) for an animal this size gives the
closest match to the human incidence curve (where k ¼ 6)
and is slightly below with a lifetime risk of only 1.5%.
Another hypothesis that has been proposed to explain
Peto’s paradox involves changing the dynamics, or popu-
lation size, of the dividing stem cells in structures such as
crypts. With this model, we find that even if each crypt con-
tained only one stem cell, a whale would still be predicted to
have a lifetime colorectal cancer risk of 96%, so this is an un-
likely solution to the paradox. However, changing the stem
cell division rate from once every 4 days to once every 13
days for an animal with one thousand times more crypts
than a human reduces the lifetime cancer risk to 2.2% and
the age incidence line closely matches that of human.(b) Model 2: Wright – Fisher model of cancer incidence
We next adapted a more realistic Wright–Fisher-based model of
cancer initiation, which allows for cell lineage death [6]. We have
simplified the model to maintain a constant population of size
N, representing the crypt stem cells in the colon.
Using the same parameters (table 1) and calculating
colorectal cancer risk across body sizes, we find that the
Wright–Fisher model provides a much lower estimate of life-
time risk than the Calabrese–Shibata model. After 1000
simulations of a human colon, the 90-year cancer risk is only
0.4% and for 1000-times as many stem cells, representing a
whale colon, just over 25% of individuals get colon cancer
(figure 1c). These lower values are expected when using the
same input as in the Calabrese–Shibata model because the
incorporation of random cell lineage death lowers the prob-
ability of a cell becoming cancerous as it not only has to
accumulate all k oncogenic mutations (these can also be
thought of as k different pathways that must be disrupted in
order to achieve a cancer phenotype), but it also must avoid
being eliminated from the population. However, 25% is still
an extremely high cancer rate when only considering one











































Figure 3. Cancer gene copy numbers across mammalian genomes. The number of tumour-suppressor genes does not increase with body mass (a). Based on our
BLAST search, we find no positive correlation between tumour-suppressor genes as a whole, or GK and CT together with body mass. This was tested with a linear
regression and is true on both the linear and log scale. The log (base 10) of the mass in grams is shown here to ease visualization of the range of masses. There is a
strong linear correlation between the number of proto-oncogenes and GK (b). Based on our BLAST search for cancer gene families, the number of proto-oncogenes
and GK found in a genome are highly correlated (r2 ¼ 0.85, p-value , 0.001). Cow is the largest animal shown and has the lowest number of both gene types,





cancer type (i.e. colorectal cancer). In humans, the lifetime risk
of most individual cancers are well below 10% with the excep-
tion of breast (12.4%) and prostate cancer (16.2%) [12].
We also note that the lifetime risk of colon cancer seems to
level off around 25% for the largest species modelled (figure 1c).
This inflection point is a consequence of the probability of
losing a cell lineage becoming independent of population size
when the population is sufficiently large in a Wright–Fisher
model. The probability that a given cell in generation t has no pro-
geny in generation tþ 1 is equal to (1 2 1/N)N. As N increases,







Therefore, when N is sufficiently large, the probability of cell lin-
eage death is independent of the population size and becomes a
constant (e21 0.37), which likely explains why cancer risk
levels off when N  1010 with this model.
In this model, just one additional required hit for colon
cancer (i.e. k ¼ 7) can account for the risk due to the 1000-fold
increase in cell numbers. This one additional hit, which rep-
resents the requirement for an extra pathway/gene to be
disrupted in order to develop a cancerous phenotype, decreases
the lifetime risk of large animals, like whales, to 0.6% which
closely matches the human estimate of 0.4% for k ¼ 6.
Decreasing the mutation rate for larger animals also
greatly reduces their lifetime risk. Given 1.2  1011 crypt
stem cells, a rate of 1.3  1026 mutations (2.3-fold decrease)
per oncogenic pathway per division decreases the lifetime
risk of cancer to the same as humans. This result can also
be obtained by decreasing the cell division rate to once
every 8.5 days. This results in a lifetime risk of 0.5% and a
rate of one division every 9 days lowers this below the
human estimate to 0.2%.(c) Evolution of cancer gene families in mammalian
genomes
It should be relatively easy for a species to evolve redundant
checks on neoplastic progression by duplicating tumour-
suppressor genes, which would present as expanded gene
families in those species. Alternatively, a species could
decrease the risk of progression by deleting proto-oncogenes
[17]. We developed a genome-wide BLAST search intended
to find all genes within a gene family based on one represen-
tative. We used the TP53 gene family (TP53, TP63 and TP73)
as our positive control, with TP53 as the query gene. In order
for a BLAST hit to be considered as an instance of the given
gene family, we required that it pass several filters based on
coverage, significance, function and location (see §4 Material
and methods). We applied the BLAST search and filters to a
highly curated set of 81 cancer genes to count the number of
proto-oncogenes and tumour-suppressor genes in eight
mammalian genomes. The tumour-suppressor genes were
further subdivided into ‘gatekeepers’ (GK) and ‘caretakers’
(CT) [18]. CT help maintain genome integrity by preventing
DNA damage and performing DNA repair. These functions
evolved billions of years before multi-cellularity and are essen-
tial to all forms of life [19]. GK control cell proliferation and
signalling by enforcing checkpoints to ensure that cells at risk
for neoplastic transformation do not continue to propagate.
We did not find a positive correlation between body mass
and the number of genome hits for any of the cancer gene cat-
egories (proto-oncogenes, GK and CT; tumour-suppressor
gene results are shown in figure 3).
There is a weak negative correlation between body mass
and the number of gatekeeper genes (R2 ¼ 0.66, p-value ¼
0.015) or proto-oncogenes (R2 ¼ 0.51, p-value ¼ 0.047). The
relationship is also true for the combination of GK and CT;
however, CT alone do not show any significant correlation
with mass (R2 ¼ 0.37, p-value ¼ 0.10) (figure 3a). These
Table 2. Tumour-suppressor genes amplified in non-human mammals. This
list includes all tumour-suppressor genes that we found to have at least
four additional copies (i.e. five total copies) in mammalian genomes based










IL6 tree shrew Tupaia belangeri 12





ING4 rock hyrax Procavia capensis 9
ALOX15 microbat M. lucifugus 8




guinea pig C. porcellus 6
AKR1B10 rat Rattus norvegicus 7




TCEB2 rat R. norvegicus 7
TNFRSF 10A pig Sus scrofa 7
TNFRSF 10B pig S. scrofa 7
AKR1B1 rat R. norvegicus 6
SLIT2 cat Felis catus 6
CST5 rat R. norvegicus 5








5negative associations are driven solely by the lower counts
found in cow and are completely abolished if the cow data-
point is removed from the analysis. Interestingly, we found
a strong correlation between the number of proto-oncogene
and GK genes, which seems independent of size (R2 ¼ 0.85,
p-value , 0.001) (figure 3b). We do not find this relationship
between proto-oncogenes and CT (R2 ¼ 0.13, p-value ¼ 0.36).
There are no significant relationships between the number of
genes in any of the cancer gene categories and lifespan, or the
product of mass times lifespan.
(d) Copy number of specific tumour-suppressor genes
in mammals
Our BLAST analysis above is not sensitive enough to pick up
small changes in individual gene copy numbers so we examined
the copy number of specific tumour-suppressor genes in mam-
mals. We focused on increased copies of tumour-suppressor
genes as it is difficult to confirm a gene deletion in draft genomes
due to possible incompleteness and mis-assemblies.
We used a comprehensive list of 830 human tumour-
suppressor genes [20] and obtained the orthologous genes in
36 non-human mammals from ENSEMBLBIOMART v. 72 (see elec-
tronic supplementary material, table S3). Genes that were found
to have a ‘one : many’ relationship to the human tumour-
suppressor gene in at least one mammal were considered for
further analysis. Our results revealed that for 382 of the genes
(46%), at least one species has one or more additional ortho-
logues to the human gene, though often these are listed in the
database as ‘apparent orthologues’ and are not high confidence
calls. Only 11% of the genes (99) have three or more paralogues
in at least one mammal and this decreases to a set of 36 genes
(4.3%) when we require a minimum of four copies of a gene.
To limit false positives due to the unknown certainty of low
copy number increases, we focused on the instances of extreme
gene amplification. We found that 19 tumour-suppressor genes
had five or more paralagous genes (i.e. at least four extra copies
relative to the human genome) (table 2). Some genes in the list
(e.g. IL6 and CTGF) are perhaps better known for oncogenic
activity; however, they are included in the list of 830 genes
because there are published reports of them demonstrating
tumour suppressive behaviour in certain tissues [20].
Our results show a number of interesting outliers with
evidence of massive gene amplification (table 2). The most
extreme case is the FBXO31 gene in the microbat (Myotis
lucifugus) with 63 annotated copies. No other mammalian
genome in the ENSEMBL database has more than one copy of this
gene; however, the recent publication of the Brandt’s bat
(Myotis brandtii) genome reveals 57 copies of FBXO31 [21]. This
gene encodes an F-box protein that mediates the DNA damage
response by promoting the degradation of cyclin D1 through
polyubiquitination to induce cell cycle arrest in G1 [22]. Though
the microbat is only 10 g, it can for live up to 34 years [14] so
one hypothesis is that these additional tumour-suppressors
may decrease the cancer risk of the bat, which would otherwise
be heightened by their increased longevity [23].
The second highest gene copy number we came across
was 12 which included TP53, IL6 and LCN2. TP53 is mutated
in the majority of human cancers and plays a crucial role in
multiple tumour suppressive pathways including apoptosis,
senescence and DNA repair [24]. Redundant copies of this
gene could greatly reduce the risk of tumorigenesis and has
been experimentally shown in mice [25].Additionally, the African elephant genome has five copies
of LIF (leukaemia inhibitory factor). LIF is a target of p53 and
can induce cell differentiation in immune cells [26]. However,
the closest sequenced relative to the African elephant, the
hyrax (Procavia capensis), has seven copies of LIF. When we
looked at the mammals with less than five copies, we found
that the lesser hedgehog tenrec (Echinops telfairi) also has
three copies of the gene so we can assume that this amplifica-
tion occurred before the divergence of these species within
Afrotheria and, though it may be biologically interesting, it
is not likely an explanation for Peto’s paradox.
The other species listed in table 2 that are of interest
include the horse (Equus caballus) and cow (Bos taurus). The
horse draft genome (EquCab2) has eight orthologues to the
human tumour-suppressor gene MAL, which are located in
tandem on scaffold 15. The only other species in the database
with any duplicate copies is the microbat with a total of two




6and apical transport of membrane and secretory proteins
[28–30]. Downregulation of this gene has been linked to
multiple epithelial cancers, including colon, cervical and
oesophageal [31–33]. The tumour suppressive properties of
MAL have been verified in head and neck squamous cell car-
cinoma where the decrease of expression is associated with
tumorigenesis, and the exogenous expression of MAL
decreased cell proliferation and increased apoptosis [34].
The final gene from our analysis with more than four
copies in a large organism is IFNB1 found in the cow. This
gene belongs to the class of interferon genes known for
their role in triggering the immune response to eradicate
pathogens and tumour cells [35,36]. However, we also see
the same number of redundant copies (five) in the squirrel
genome and two copies (i.e. one extra copy) in the guinea
pig, horse and hyrax genomes, which makes it less likely to
be directly involved with enhanced tumour suppression in
large, long-lived animals. 0:201402223. Discussion
Essentially, all models are wrong, but some are useful.
—George E. P. Box [37, p. 424]The algebraic and Wright–Fisher models used in this analysis
are not intended to represent accurately the complexity of
neoplastic progression; however, they are still useful for evaluat-
ing potential solutions to Peto’s paradox. Interestingly, we find
that the parameter changes that would be necessary to resolve
Peto’s paradox in large organisms fall within normal biological
constraints. There is still much work to be done in the field to
obtain more accurate estimates of human somatic mutation
rates, as reported values span orders of magnitude and range
from 10211 to 1029 mutations/base/division [38–42]. Though
the estimates are not perfect, slight differences in mutation
rate across species have been observed. For example, one study
that derives somatic mutation rates from specific loci across eu-
karyotes found that the per base mutation rates for human and
mouse are 5.0 10211 and 1.8 10210, respectively [39]. This is
a 3.6-fold decrease in mutation rate in human versus mouse and
is remarkably close to the results of our modelling, which suggest
that a two- to threefold decrease in mutation rate can account for a
1000-fold difference in body size between mice and humans. This
effective decrease in mutation rate may be accomplished by
having better DNA repair in the larger species, more efficient
removal of mutated cells, or less endogenous damage as a
result of a lower mass-specific basal metabolic rate [2].
To decrease the lifetime risk of colon cancer sufficiently in
large animals such as whales, we estimated that the stem cell
division rate would only have to decrease from once every
4 days to once every 8.5 days, or 13 days, depending on the
model. Crypt stem cells in mice divide once a day [43]; how-
ever, human measurements are limited and are estimated to
be at least once per week [44,45]. One could investigate this
by measuring the mitotic index of colonic crypts across
species spanning orders of magnitude in size.
We were also able to resolve Peto’s paradox by increasing
the number of rate-limiting hits required for transformation.
Both models show that with just one or two additional hits,
the risk of cancer can be greatly reduced in large animals.
Therefore, we might anticipate finding functionally redundant
pathways or additional tumour-suppressor genes that act as a
‘back up’ in case of failure to existing pathways in animals thathave evolved this tumour suppression mechanism better to
combat cancer, which has been previously proposed as a
solution to Peto’s paradox [2,10,46]. The implications of this
are not entirely straightforward though, as duplication of a
tumour-suppressor gene could still have a dominant negative
effect on the wild-type copies and would therefore not add
the same type of protection as an independent gene with func-
tional redundancy. However, our analysis of published animal
genomes does not support our initial hypothesis that the total
number of tumour-suppressor genes is increased in proportion
to body mass.
Though we were able to use simple models to gain insight
into a complicated disease, there are many assumptions that go
into these models that we must acknowledge when interpreting
the results. These models assume that all mutations are evolution-
arily neutral for cell-level selection. The model also assumes a
constant cell population size and mutation rate. Additionally,
all k mutations necessary for cancer are required to occur in
one single cell, which ignores the possibility of cell cooperation
[47] and does not address clonal expansions, which would dras-
tically alter the time to accumulate the mutations [48]. When
oncogenic clones with a fitness advantage expand in the popu-
lation, this greatly increases the chance that another oncogenic
event will occur in a cell harbouring the prior mutation, which
could decrease the time required for the evolution of malignant
cells. Our model implementation does not consider fitness and
selection of clones which limit its ability to realistically depict
cancer; however, we can still gain theoretical insights and test
hypotheses which could be pursued in the future with more
appropriately detailed models and experiments.
Both models also assume that the rate-limiting step in
carcinogenesis is the accumulation of oncogenic point
mutations; however, other events can affect tumour initiation
and progression. We do not address genetic changes involving
chromosomal rearrangements, copy number changes, nor does
this study consider epigenetic changes or alterations to the
tissue microenvironment. This was done to gain an initial
understanding of the parameters involved in carcinogenesis;
however, all of the conditions and events listed above may be
important in vivo and we are currently not capturing their
contributions. Previous work has shown that within rodents,
repression of telomerase activity (and therefore replica-
tive senescence—an anti-cancer mechanism) coevolved with
increased body mass, such that larger species have decreased
expression [49]. This, along with other comparative studies
revealing changes in expression in correlation with body size
and/or lifespan [49–54], stresses the importance of continuing
to expand our analysis of tumour suppression mechanisms in
large long-lived organisms since evolution was not constrained
to the set of parameters we have examined here.
The Wright–Fisher model (model 2) was originally devel-
oped to model one single crypt as it progresses from a benign
polyp to an invasive tumour [6]. We have expanded the initial
cell population to represent all stem cells in the colon; however,
this ignores the compartmentalization structure provided by
crypts, which are considered a barrier for the clonal expansion
of pre-malignant cells [55,56]. This simplification to our model
was made to reduce drastically the computational complexity
and allowed for more direct comparisons with the Calabrese–
Shibata model (model 1), which also did not consider the effects
of the crypt structure.
A major caveat in this study is the difficulty in verifying a




7incomplete assemblies, mis-assemblies and inaccurate anno-
tations. There may also be undetected cancer genes in
non-human species with little homology to the human gene
sequences. However, we added the time since the most
recent common ancestor with human to our linear model, to
account for the difficulty of detecting genes with low levels
of homology due to evolutionary distance, and this did not
change the results, suggesting that the number of genes we
find in each species is not simply a function of how closely
they are related to humans. Human tumour-suppressor
genes were used for this analysis, but in doing so we made
the assumption that they perform the same function in the
other species. This has not been experimentally verified.
Additionally, we limited ourselves to these known tumour-
suppressor genes, but there may be additional genes acting
as tumour suppressors in other species that would have been
missed, in addition to possible flaws in our filtering criteria
that could cause some genes to be missed. As an example,
we set the requirement that for two hits to be considered as
separate instances of a query gene, they had to be at least
1 Mb apart; however, if a gene were duplicated in a tandem
repeat, we would likely only count them as one copy.
Despite these limitations, we found genes that have been
dramatically amplified in specific mammalian genomes, the
most interesting of which is the discovery of 12 TP53 copies in
the genome of the African elephant. We subsequently cloned
those genes and identified 19 distinct copies of TP53 in African
elephants and 15–20 in Asian elephants [1]. Another potential
lead for solving Peto’s paradox is MAL, which is found to have
eight copies in the horse genome and two in microbat. This
could be an example of convergent evolution where a large
animal (horse) and a small, long-lived animal (microbat) both
evolved extra copies of the same gene to overcome their
increased risk of cancer. Further analysis and experimenta-
tion would need to be performed to determine the function
of these copies and whether or not they provide enhanced
suppression of carcinogenesis.
The goal of this analysis was to gain theoretical insight
into the most realistic hypotheses to resolve Peto’s paradox,
rather than precise parameter estimations. We found that
decreasing the mutation rate or division rate, or increasing
the number of required mutations can all sufficiently reduce
the lifetime cancer risk in an animal orders of magnitude
larger than a human; however, decreasing the number of
stem cells per crypt (or epithelial proliferative unit) is not a
likely solution. The necessary changes in the mutation rates
and number of required hits are small and are well within
biologically feasible ranges. These values should be the
focus of future experiments designed to measure the somatic
mutation rates, stem cell generation times and the number of
pathways that must be mutated to transform cells across
species that span a wide range of sizes and lifespans. These
data in the future may serve to identity the most effective
strategies to prevent human cancer.4. Material and methods
(a) Justification for assuming that colon crypt count
scales with body mass
A human colon is on average 1.5 m long and 6 cm in diameter [57],
which gives an approximate area of 3  103 cm2 (i.e. diameter p  length). The total number of crypts is estimated to be 1.5 
107 [58,59], so the crypt density is approximately 5000 crypts per
cm2. A mouse, which is three orders of magnitude smaller than a
human, has roughly 6 cm2 of colon (6 cm long and 0.3 cm in diam-
eter) [59]. Using the same crypt density, we calculate there to be
approximately 3  104 crypts in a mouse colon, which is the
expected three orders of magnitude difference.
(b) Calabrese – Shibata model
The Calabrese–Shibata model, which we have repurposed to
explore solutions to Peto’s paradox, was originally detailed in
previous publications [7,11]. We use the same equation to calcu-
late the risk of colorectal cancer given the age of the individual:
p ¼ 1 (1 (1 (1 u)d)k)Nm,
where u is the mutation rate per gene per division, d is the
number of stem cell divisions since birth, k is the number of
rate-limiting mutations required for cancer to occur, N is the
number of effective stem cells per crypt and m is the number
of crypts per colon [7]. We wrote a script in C (source code avail-
able upon request) to run through the model using ranges for
each parameter and the results were plotted in R.
(c) Wright – Fisher model
The Wright–Fisher model represents a constant population size,
with non-overlapping generations, where each cell of the new
generation choses a parent cell from which to inherit its
mutant status. This occurs with equal probability (1/N ) because
we are not considering selective coefficients, to make it more
comparable to the Calabrese–Shibata model and avoid using
parameters that lack good experimental measurements. Given a
population of N cells, the probability of a configuration of cells
with 0 to k mutations at a given time (t þ 1) can be expressed
using the following multinomial distribution:
[N0(tþ 1), . . . , Nk(tþ 1)] 
N(t)!






where N(t) is the size of the total population at time t, Nj(t) is the
population size of cells at time t with j mutations and uj is the








where u is the mutation rate per gene per generation, d is the
number of potential driver genes and xi(t) is the fraction of cells
with i mutations at time t. The number of potential driver genes
d was set to six in this study to be comparable with the algebraic
model having the parameters listed in table 1. This has been
formally detailed in the original publication [6]. In our implemen-
tation, each instance of the model represents one colon with
N crypt stem cells and all mutations are neutral. For each set of par-
ameters, the model was run 1000 times to estimate the frequency of
cancer. We ran a minimum of three independent replicates of the
1000 runs to make sure the number of cases reported to have
cancer (i.e. contain k mutations) was consistent and we averaged
across the replicates. R was used to visualize and plot the data.
(d) BLAST analysis for gene family expansions
We retrieved protein sequences of more than 300 genes from the
Cancer Genome Anatomy Project (CGAP) website [60]. We
focused on genes with either oncogene (22 genes) or tumour-
suppressor (59 genes) classification by CGAP (electronic sup-
plementary material, table S1). Other genes were classified as
partners of fusion genes by CGAP and were excluded from our




8two groups: CT (28 genes) if the gene had gene ontology annota-
tions suggesting their functionality in DNA damage repair;
otherwise genes were classified as GK (31 genes). We used the
NCBI gene ontology annotation for human and checked for
each gene whether it was associated with a gene ontology term
(or a descendant of such term in the gene ontology hierarchy)
having ‘DNA damage’ or ‘DNA repair’ in its description.
Genomes from the NCBI RefSeq database were used as
BLAST databases against the 81 human cancer-related query
genes to count the number of total hits in each genome. We lim-
ited the analysis to fully sequenced mammals at the time of
analysis: cow, chimp, dog, horse, macaque, mouse, opossum
and rat. For a BLAST hit to count as an independent instance
of that gene in a given genome, it had to meet our criteria of cov-
erage, significance, location, reciprocity and functionality. First,
the union of all hits to that sequence in the subject’s genome
must cover at least 50% of the human query gene. Second, one
of the BLAST hits in this region must have an e-value  1025
and all other hits counting towards the 50% coverage must
have e-values  1023. Third, the BLAST hit must be greater
than 1 Mb away from any other determined location of the
query gene in the given subject genome. The location of hits
for each organism, based on these criteria, was used as input
into the UCSC genome browser to retrieve the predicted protein
sequences determined by the N-SCAN algorithm. These
sequences were then used for a reciprocal BLAST back to
human RefSeq protein sequences (release 37). For a region to
count as a true hit in a non-human species, the predicted protein
sequence must return a top hit in the human genome that is
either the original human query gene that produced that hit, or
a paralogous gene. Paralogues were defined by the ENSEMBL
genome browser (release 56). N-SCAN was also used to deter-
mine the functionality of the genomic regions to exclude
known pseudogenes and intergenic regions that were not pre-
dicted to be genes. These criteria were determined by
comparison of our results to known p53 gene families
(as reported by ENSEMBL release 56) as a positive control. The
numbers of hits for each of the 81 individual genes were tallied
as proto-oncogenes, CT and GK for each organism.
Body mass data [14,61] and the evolutionary distance from
humans were taken from the literature [62–66]. We fit a linear
regression model to the data (electronic supplementary material,
table S2) using the statistical package R to determine the relation-
ship between the number of each gene type (proto-oncogenes,
CT and GK) and the animal’s body mass (representing the
total number of cells in the organism). We tested this on both a
log and linear scale.
(e) Determining copy number of tumour-suppressor
genes
A list of 830 tumour-suppressor genes was downloaded from the
Memorial Sloan Kettering CancerGenes database [20] (for full listsee electronic supplementary material, table S3). This list
includes all genes that have been associated with tumour sup-
pressive behaviour in at least one instance and have been
assigned gene ontology terms related to these functions such as
‘positive regulation of apoptosis’ and ‘negative regulation of
cell proliferation’. Genes appear in this list regardless of whether
or not they also have been reported to have oncogenic properties.
We obtained the orthologous relationships for 36 non-human
mammals from ENSEMBL BIOMART v. 72: alpaca (Vicugna pacos),
armadillo (Dasypus novemcinctus), bushbaby (Otolemur garnettii),
cat (Felis catus), chimpanzee (Pan troglodytes), common shrew
(Sorex araneus), cow (B. taurus), dog (Canis lupus familiaris), dol-
phin (Tursiops truncatus), African elephant (Loxodonta africana),
ferret (Mustela putorius furo), gibbon (Nomascus leucogenys), gor-
illa (Gorilla gorilla gorilla), guinea pig (Cavia porcellus), hedgehog
(Erinaceus europaeus), horse (E. caballus), kangaroo rat (Dipodomys
ordii), lesser hedgehog tenrec (E. telfairi), macaque (Macaca
mulatta), marmoset (Callithrix jacchus), megabat (Pteropus
vampyrus), microbat (M. lucifugus), mouse (Mus musculus),
mouse lemur (Microcebus murinus), opossum (Monodelphis domes-
tica), orangutan (Pongo abelii), panda (Ailuropoda melanoleuca), pig
(Sus scrofa), rabbit (Oryctolagus cuniculus), rat (Rattus norvegicus),
rock hyrax (P. capensis), sloth (Choloepus hoffmanni), squirrel
(Ictidomys tridecemlineatus), tarsier (Tarsius syrichta), Tasmanian
devil (Sarcophilus harrisii) and tree shrew (Tupaia belangeri).
A phylogeny of the mammals used in this study is provided in
electronic supplementary material, figure S1.
Genes that were found to have a ‘one : many’ relationship, as
annotated by ENSEMBL, to the human tumour-suppressor gene in
at least on mammal were considered for downstream analysis.
The top genes were filtered based on the maximum number of
times they occurred in any one species. All genes in table 2
occurred at least five times in the species indicated. The entire
matrix of genes and copy number in each species is provided
in the electronic supplementary material, table S3.Data accessibility. The datasets supporting this article have been
uploaded as part of the electronic supplementary material.
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estuary, Québec, Canada. Environ. Health Perspect.
110, 285 – 292. (doi:10.1289/ehp.02110285)
16. Newman SJ, Smith SA. 2006 Marine mammal
neoplasia: a review. Vet. Pathol. 43, 865 – 880.
(doi:10.1354/vp.43-6-865)
17. Davenport MP, Ward RL, Hawkins NJ. 2002 The null
oncogene hypothesis and protection from cancer.
J. Med. Genet. 39, 12 – 14. (doi:10.1136/jmg.39.1.12)
18. Kinzler KW, Vogelstein B. 1997 Cancer-susceptibility
genes. Gatekeepers and caretakers. Nature 386,
761 – 763. (doi:10.1038/386761a0)
19. Domazet-Loso T, Tautz D. 2010 Phylostratigraphic
tracking of cancer genes suggests a link to the
emergence of multicellularity in metazoa. BMC Biol.
8, 66. (doi:10.1186/1741-7007-8-66)
20. Higgins ME, Claremont M, Major JE, Sander C, Lash
AE. 2007 CancerGenes: a gene selection resource for
cancer genome projects. Nucleic Acids Res. 35,
D721 – D726. (doi:10.1093/nar/gkl811)
21. Seim I et al. 2013 Genome analysis reveals insights
into physiology and longevity of the Brandt’s bat
Myotis brandtii. Nat. Commun. 4, 2212. (doi:10.
1038/ncomms3212)
22. Santra MK, Wajapeyee N, Green MR. 2009 F-box
protein FBXO31 mediates cyclin D1 degradation to
induce G1 arrest after DNA damage. Nature 459,
722 – 725. (doi:10.1038/nature08011)
23. Danilov A et al. 2013 Selective anticancer agents suppress
aging in Drosophila. Oncotarget 4, 1507 – 1526.
24. Hollstein M, Sidransky D, Vogelstein B, Harris C.
1991 p53 mutations in human cancers. Science 253,
49 – 53. (doi:10.1126/science.1905840)25. Garcia-Cao I, Garcı́a-Cao M, Martı́n-Caballero J,
Criado LM, Klatt P, Flores JM, Weill J-C, Blasco MA,
Serrano M. 2002 ‘Super p530 mice exhibit enhanced
DNA damage response, are tumor resistant and age
normally. EMBO J. 21, 6225 – 6235. (doi:10.1093/
emboj/cdf595)
26. Gearing DP et al. 1987 Molecular cloning and
expression of cDNA encoding a murine myeloid
leukaemia inhibitory factor (LIF). EMBO J. 6,
3995 – 4002.
27. Alonso MA, Weissman SM. 1987 cDNA cloning and
sequence of MAL, a hydrophobic protein associated
with human T-cell differentiation. Proc. Natl Acad. Sci.
USA 84, 1997 – 2001. (doi:10.1073/pnas.84.7.1997)
28. Cheong KH, Zacchetti D, Schneeberger EE, Simons K.
1999 VIP17/MAL, a lipid raft-associated protein, is
involved in apical transport in MDCK cells. Proc. Natl
Acad. Sci. USA 96, 6241 – 6248. (doi:10.1073/pnas.
96.11.6241)
29. Puertollano R, Alonso MA. 1999 Substitution of the
two carboxyl-terminal serines by alanine causes
retention of MAL, a component of the apical sorting
machinery, in the endoplasmic reticulum. Biochem.
Biophys. Res. Commun. 260, 188 – 192. (doi:10.
1006/bbrc.1999.0876)
30. Puertollano R, Alonso MA. 1999 Targeting of MAL, a
putative element of the apical sorting machinery, to
glycolipid-enriched membranes requires a pre-Golgi
sorting event. Biochem. Biophys. Res. Commun. 254,
689 – 692. (doi:10.1006/bbrc.1998.0122)
31. Horne HN, Lee PS, Murphy SK, Alonso MA, Olson JA,
Marks JR. 2009 Inactivation of the MAL gene in
breast cancer is a common event that predicts
benefit from adjuvant chemotherapy. Mol. Cancer
Res. 7, 199 – 209. (doi:10.1158/1541-7786.MCR-
08-0314)
32. Lind GE et al. 2008 Hypermethylated MAL gene –
a silent marker of early colon tumorigenesis.
J. Transl. Med. 6, 13. (doi:10.1186/1479-5876-6-13)
33. Mimori K et al. 2003 MAL gene expression in
esophageal cancer suppresses motility, invasion and
tumorigenicity and enhances apoptosis through the
Fas pathway. Oncogene 22, 3463 – 3471. (doi:10.
1038/sj.onc.1206378)
34. Cao W, Zhang Z, Xu Q, Sun Q, Yan M, Zhang J,
Zhang P, Han Z, Chen W. 2010 Epigenetic silencing
of MAL, a putative tumor suppressor gene, can
contribute to human epithelium cell carcinoma.
Mol. Cancer 9, 296. (doi:10.1186/1476-4598-9-296)
35. Siegal FP et al. 1999 The nature of the principal
type 1 interferon-producing cells in human blood.
Science 284, 1835 – 1837. (doi:10.1126/science.284.
5421.1835)
36. Takaoka A et al. 2003 Integration of interferon-a/b
signalling to p53 responses in tumour suppression
and antiviral defence. Nature 424, 516 – 523.
(doi:10.1038/nature01850)
37. Box GEP, Draper NR. 1987 Empirical model-building
and response surfaces. New York, NY: Wiley.
38. Chu EH, Boehnke M, Hanash SM, Kuick RD, Lamb
BJ, Neel JV, Niezgoda W, Pivirotto S, Sundling G.
1988 Estimation of mutation rates based on the
analysis of polypeptide constituents of culturedhuman lymphoblastoid cells. Genetics 119,
693 – 703.
39. Drake JW, Charlesworth B, Charlesworth D, Crow JF.
1998 Rates of spontaneous mutation. Genetics 148,
1667 – 1686.
40. Jones S et al. 2008 Comparative lesion sequencing
provides insights into tumor evolution. Proc. Natl
Acad. Sci. USA 105, 4283 – 4288. (doi:10.1073/pnas.
0712345105)
41. Loeb LA. 1991 Mutator phenotype may be required
for multistage carcinogenesis. Cancer Res. 51,
3075 – 3079.
42. Strauss BS. 1992 The origin of point mutations in
human tumor cells. Cancer Res. 52, 249 – 253.
43. Snippert HJ et al. 2010 Intestinal crypt homeostasis
results from neutral competition between
symmetrically dividing Lgr5 stem cells. Cell 143,
134 – 144. (doi:10.1016/j.cell.2010.09.016)
44. Kang H, Shibata D. 2013 Direct measurements of
human colon crypt stem cell niche genetic fidelity:
the role of chance in non-Darwinian mutation
selection. Front. Oncol. 3, 264. (doi:10.3389/fonc.
2013.00264)
45. Wright NA, Alison M. 1984 The biology of epithelial
cell populations. Oxford, UK: Oxford Science.
46. Leroi A, Koufopanou V, Burt A. 2003 Cancer
selection. Nat. Rev. Cancer 3, 226 – 231. (doi:10.
1038/nrc1016)
47. Axelrod R, Axelrod DE, Pienta KJ. 2006 Evolution of
cooperation among tumor cells. Proc. Natl Acad. Sci. USA
103, 13 474– 13 479. (doi:10.1073/pnas.0606053103)
48. Nowell PC. 1976 The clonal evolution of tumor cell
populations. Science 194, 23 – 28. (doi:10.1126/
science.959840)
49. Seluanov A, Chen Z, Hine C, Sasahara THC, Ribeiro
AACM, Catania KC, Presgraves DC, Gorbunova V.
2007 Telomerase activity coevolves with body mass
not lifespan. Aging Cell 6, 45 – 52. (doi:10.1111/j.
1474-9726.2006.00262.x)
50. Gorbunova V, Seluanov A. 2009 Coevolution of
telomerase activity and body mass in mammals:
from mice to beavers. Mech. Ageing Dev. 130, 3 – 9.
(doi:10.1016/j.mad.2008.02.008)
51. Gorbunova V, Zhang Z, Gladyshev VN, Vijg J. 2014
Comparative genetics of longevity and cancer:
insights from long-lived rodents. Nat. Rev. Genet.
15, 531 – 540. (doi:10.1038/nrg3728)
52. Seluanov A, Hine C, Azpurua J, Feigenson M,
Bozzella M, Mao Z, Catania KC, Gorbunova V. 2009
Hypersensitivity to contact inhibition provides a clue
to cancer resistance of naked mole-rat. Proc. Natl
Acad. Sci. USA 106, 19 352 – 19 357. (doi:10.1073/
pnas.0905252106)
53. Seluanov A et al. 2008 Distinct tumor suppressor
mechanisms evolve in rodent species that differ in
size and lifespan. Aging Cell 7, 813 – 823. (doi:10.
1111/j.1474-9726.2008.00431.x)
54. Tian X et al. 2013 High-molecular-mass hyaluronan
mediates the cancer resistance of the naked mole rat.
Nature 499, 346 – 349. (doi:10.1038/nature12234)
55. Cairns J. 1975 Mutation selection and the natural




1056. Gatenby R, Gillies R, Brown J. 2010 The evolutionary
dynamics of cancer prevention. Nat. Rev. Cancer 10,
526 – 527. (doi:10.1038/nrc2892)
57. Horton KM, Corl FM, Fishman EK. 2000 CT
evaluation of the colon: inflammatory disease.
Radiographics 20, 399 – 418. (doi:10.1148/
radiographics.20.2.g00mc15399)
58. Yatabe Y, Tavare S, Shibata D. 2001 Investigating
stem cells in human colon by using methylation
patterns. Proc. Natl Acad. Sci. USA 98, 10 839 –
10 844. (doi:10.1073/pnas.191225998)
59. Pickhardt PJ, Halberg RB, Taylor AJ, Durkee BY, Fine
J, Lee FT, Weichert JP. 2005 Microcomputed
tomography colonography for polyp detection in anin vivo mouse tumor model. Proc. Natl Acad. Sci.
USA 102, 3419 – 3422. (doi:10.1073/pnas.
0409915102)
60. Riggins GJ, Strausberg RL. 2001 Genome and
genetic resources from the Cancer Genome Anatomy
Project. Hum. Mol. Genet. 10, 663 – 667. (doi:10.
1093/hmg/10.7.663)
61. Smith FA. 2003 Body mass of Late Quaternary
mammals. Ecology 84, 3403. (doi:10.1890/02-9003)
62. Bininda-Emonds OR et al. 2007 The delayed rise
of present-day mammals. Nature 446, 507 – 512.
(doi:10.1038/nature05634)
63. Chen FC, Li WH. 2001 Genomic divergences
between humans and other hominoids and theeffective population size of the common ancestor of
humans and chimpanzees. Am. J. Hum. Genet. 68,
444 – 456. (doi:10.1086/318206)
64. Gibbs RA et al. 2007 Evolutionary and biomedical
insights from the rhesus macaque genome. Science
316, 222 – 234. (doi:10.1126/science.1139247)
65. Murphy WJ, Pringle TH, Crider TA, Springer MS,
Miller W. 2007 Using genomic data to unravel the
root of the placental mammal phylogeny. Genome
Res. 17, 413 – 421. (doi:10.1101/gr.5918807)
66. Patterson N, Richter DJ, Gnerre S, Lander ES,
Reich D. 2006 Genetic evidence for complex
speciation of humans and chimpanzees. Nature
441, 1103 – 1108. (doi:10.1038/nature04789).R.Soc.B
370:20140222
